Information mensuelle relative au nombre total des droits de vote et dactions composant le capital social
| CLLS Stock | USD 3.02 0.07 2.37% |
Slightly above 55% of Cellectis' private investors are presently thinking to get in. The analysis of overall sentiment of trading Cellectis SA stock suggests that some investors are interested at this time. Cellectis' investing sentiment can be driven by a variety of factors including economic data, Cellectis' earnings reports, geopolitical events, and overall market trends.
Cellectis | Build AI portfolio with Cellectis Stock |
PARIS, 04 juill. 2025 -- Place de cotation Euronext...
Read at globenewswire.com
 |
Cellectis Fundamental Analysis
We analyze Cellectis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Cellectis is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Cellectis SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectis stock to make a market-neutral strategy. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics with similar companies.
Peers
Cellectis Related Equities
| FATE | Fate Therapeutics | 2.83 | ||||
| GNFT | Genfit SA | 0.26 | ||||
| MGTX | MeiraGTx Holdings | 0.77 | ||||
| MCRB | Seres Therapeutics | 1.83 | ||||
| IPHA | Innate Pharma | 1.86 | ||||
| ATRA | Atara Biotherapeutics | 1.99 | ||||
| SGMO | Sangamo Therapeutics | 2.24 | ||||
| CCCC | C4 Therapeutics | 4.29 |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.